DURECT Corp (OQ:DRRX)

Mar 27, 2024 04:01 pm ET
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Ongoing Communication with FDA to Align on Next Steps for Larsucosterol in Alcohol-Associated Hepatitis
Feb 22, 2024 08:31 am ET
Thinking about buying stock in Vermilion Energy, Staffing 360 Solutions, DURECT, Root Inc, or Ventyx Biosciences?
NEW YORK, Feb. 22, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VET, STAF, DRRX, ROOT, and VTYX.
Feb 07, 2024 05:48 pm ET
DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
CUPERTINO, Calif., Feb. 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and Chief Executive Officer, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually, February 13-14, 2024.
Nov 13, 2023 03:05 pm ET
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update
-  Webcast of Earnings Call Today, November 13th at 4:30 p.m. ET
Nov 09, 2023 03:30 pm ET
DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update
CUPERTINO, Calif., Nov. 9, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its financial results for the three months ended September 30, 2023 on Monday, November 13, 2023. Management will also host a conference call and webcast with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time. Details for the
Nov 07, 2023 03:01 pm ET
DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality
Compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality at 90 days.  Clinically relevant reduction in 90-day mortality of 41% for 30 mg dose and 35% for 90 mg dose compared with standard of care (SOC)
Jul 20, 2023 08:00 am ET
DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
CUPERTINO, Calif., July 20, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of acute organ injury and chronic liver diseases, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 2,991,027 shares of common stock and accompanying warrants to purchase up to 2,991,027 shares of common stock in a registered direct offering (the "Offering") priced at-the-market under Nasdaq rules. The shares of common stock and accompanying
May 08, 2023 04:05 pm ET
DURECT Corporation Reports First Quarter 2023 Financial Results and Business Update
- Webcast of Earnings Call Today, May 8th at 4:30 p.m. ET
May 01, 2023 07:03 pm ET
DURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8
CUPERTINO, Calif., May 1, 2023 /PRNewswire/ --- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2023 financial results and host a conference call after the market close on Monday, May 8, 2023.
Apr 27, 2023 05:11 pm ET
DURECT Corporation to Host KOL Event on Alcohol-Associated Hepatitis
CUPERTINO, Calif., April 27, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it will host a Key Opinion Leader ("KOL") event on Alcohol-Associated Hepatitis on May 16th in New York City. Topics of discussion will include the etiology and prevalence of alcohol-associated hepatitis (AH), current treatment insufficiencies and unmet need for patients with AH, biology of larsucosterol, trial design and status update for the Phase 2b AHFIRM trial in AH, and a company update on regulatory and commercial efforts ongoing for larsucosterol in AH. In addition to company managemen
Apr 25, 2023 06:45 pm ET
DURECT Corporation to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference
CUPERTINO, Calif., April 25, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO, will participate in a fireside chat hosted by Ed Arce, Managing Director, Senior Biotechnology Research Analyst, H.C Wainwright & Co., LLC at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023.
Apr 10, 2023 06:00 am ET
DURECT Announces Peer-Reviewed Article Accepted for Publication with Additional Data from Previously Completed Phase 2a Study of Larsucosterol in Alcohol-Associated Hepatitis
Data expands upon previously reported results, including individual patient data, additional liver biomarkers, and comparisons to matching arms from a contemporaneous study
Mar 21, 2023 04:30 pm ET
DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board
CUPERTINO, Calif., March 21, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023.  Ms. Maderis succeeds David Hoffmann as Chair of the Board. Mr. Hoffman has decided not to stand for re-election and will retire from the board on June 21, 2023 when his current term as a board member expires.   
Mar 09, 2023 07:30 am ET
DURECT Corporation Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference
CUPERTINO, Calif., March 9, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO and additional members of the management team will participate in a fireside chat hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer & Co. Inc. at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15th, 2023.
Feb 03, 2023 04:17 pm ET
DURECT Corporation Announces $10 Million Registered Direct Offering of Common Stock and Warrants
CUPERTINO, Calif., Feb. 3, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of acute organ injury and chronic liver diseases, today announced that it has entered into a definitive agreement with a leading institutional healthcare investor and an existing institutional investor for the purchase and sale of an aggregate of 1,700,000 shares of common stock and, in lieu of shares of common stock, pre-funded warrants to purchase 300,000 shares of common stock, and accompanying wa
Nov 28, 2022 05:46 pm ET
DURECT Announces 1-for-10 Reverse Stock Split
CUPERTINO, Calif., Nov. 28, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, announced that DURECT's board of directors today determined that the Company will effect a reverse stock split at a ratio of 1-for-10 as of 5:01 p.m. Eastern Time on December 5, 2022. Beginning with the opening of trading on December 6, 2022, the Company's common stock will trade on a split-adjusted basis.
Nov 02, 2022 04:05 pm ET
DURECT Corporation Reports Third Quarter 2022 Financial Results and Update of Programs
-  Webcast of Earnings Call Today, November 2nd at 4:30 p.m. ET
Oct 26, 2022 08:30 am ET
DURECT Corporation to Announce Third Quarter 2022 Financial Results and Provide Business Update on November 2
CUPERTINO, Calif., Oct. 26, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its third quarter 2022 financial results and host a conference call after the market close on Wednesday, November 2, 2022.
Oct 06, 2022 08:30 am ET
DURECT Reaches Enrollment Milestone in Phase 2b AHFIRM Trial
AHFIRM enrollment surpasses 200 of the planned 300 AH patients Enrollment completion now anticipated in Q2 2023CUPERTINO, Calif., Oct. 6, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, today announced the enrollment of more than 200 of the planned 300 patients in its Phase 2b AHFIRM trial. The AHFIRM trial seeks to evaluate larsucosterol's potential to serve as a treatment for severe alcohol-associated hepatitis (AH).
Sep 26, 2022 08:30 am ET
Innocoll and DURECT Announce U.S. launch of POSIMIR®
POSIMIR® is now commercially available in the U.S. for the treatment of post-surgical pain in adults following arthroscopic subacromial decompression surgery DURECT recently received an $8 million milestone payment for a new patent issuance and has now earned a $2 million milestone payment for first commercial sale of POSIMIRATHLONE, Ireland and CUPERTINO, Calif., Sept. 26, 2022 /PRNewswire/ -- Innocoll Pharmaceuticals Limited, a commercial-stage biotechnology  company and portfolio business of Gurnet Point Capital, and DURECT Corporation (Nasdaq: DRRX) today announced the recent commercial
Sep 06, 2022 08:00 am ET
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference
CUPERTINO, Calif., Sept. 6, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO will be presenting virtually at the H.C. Wainwright 24th annual Global Investment Conference. 
Aug 04, 2022 04:05 pm ET
DURECT Corporation Reports Second Quarter 2022 Financial Results and Update of Programs
-  Webcast of Earnings Call Today, August 4th at 4:30 p.m. ET
Jul 27, 2022 04:15 pm ET
DURECT Corporation to Announce Second Quarter 2022 Financial Results and Provide Business Update on August 4
CUPERTINO, Calif., July 27, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2022 financial results and host a conference call after the market close on Thursday, August 4, 2022.
May 18, 2022 01:53 pm ET
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference
CUPERTINO, Calif., May 18, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Dr. Norman Sussman, Chief Medical Officer, and Dr. WeiQi Lin, Executive Vice President of R&D, will be participating in a fireside chat hosted by Ed Arce, Managing Director of Equity Research at H.C. Wainwright. 
May 04, 2022 04:05 pm ET
DURECT Corporation Reports First Quarter 2022 Financial Results and Update of Programs
- Webcast of Earnings Call Today, May 4th at 4:30 p.m. ET
Apr 27, 2022 04:15 pm ET
DURECT Corporation to Announce First Quarter 2022 Financial Results and Provide Business Update on May 4
CUPERTINO, Calif., April 27, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2022 financial results and host a conference call after the market close on Wednesday, May 4, 2022.
Mar 23, 2022 04:15 pm ET
DURECT Corporation To Present at the 2022 Cantor Fitzgerald Virtual Rare Orphan Disease Summit
CUPERTINO, Calif., March 23, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, will be participating in a panel discussion at the Cantor Virtual Rare Orphan Disease Summit hosted by Kristen Kluska, Managing Director, Biotechnology Research Analyst of Cantor Fitzgerald.  The title of the panel is "Small but Mighty: Innovative Strategies in Tackling Some of the Larger Rare Orphan Disease Markets" and will take place at 1:00 pm ET on Wednesday, March 30, 2022. 
Mar 09, 2022 03:30 pm ET
DURECT Corporation Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference
CUPERTINO, Calif., March 9, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Dr. WeiQi Lin, Executive Vice President of R&D and Dr. Norman Sussman, Chief Medical Officer, will be participating in a fireside chat hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer & Co. Inc. at the Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022.
Mar 07, 2022 03:05 pm ET
DURECT Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Update of Programs
CUPERTINO, Calif., March 7, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2021 and provided a corporate update.
Mar 01, 2022 07:30 am ET
DURECT Corporation Doses First European Patient in Phase 2b AHFIRM Study of Larsucosterol(DUR-928) in Severe Alcohol-Associated Hepatitis
CUPERTINO, Calif., March 1, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it dosed the first patient in the European Union as part of its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to evaluate the safety and efficacy of larsucosterol in severe alcohol-associated hepatitis (AH) patients.
Feb 28, 2022 03:30 pm ET
DURECT Corporation to Announce Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on March 7
CUPERTINO, Calif., Feb. 28, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and full year 2021 financial results and host a conference call after the market close on Monday, March 7, 2022.
Jan 06, 2022 03:05 pm ET
DURECT Corporation to Participate in H.C. Wainwright Bioconnect Conference
CUPERTINO, Calif., Jan. 6, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, and Dr. Norman Sussman, Chief Medical Officer will present at the H.C. Wainwright Bioconnect Conference which will be available on demand starting on January 10, 2022.
Dec 22, 2021 06:30 am ET
DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)
CUPERTINO, Calif. and ATHLONE, Ireland, Dec. 22, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced a licensing agreement granting Innocoll Biotherapeutics plc, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, exclusive development and commercialization rights to POSIMIR® (bupivacaine solution) for infiltration use, DURECT's FDA-approved non-opioid, sustained-release local analgesic for the treatment of post-surgical pain in adults following arthroscopic subacromial decompression surgery, in the United States.
Dec 14, 2021 08:00 am ET
DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter Garcia
CUPERTINO, Calif., Dec. 14, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the expansion of its board of directors with the appointment of Peter García, a biopharmaceutical industry veteran with over 25 years of financial leadership experience.
Nov 29, 2021 08:00 am ET
DURECT Corporation to Participate in Alcoholic Liver Disease Workshop Today at the 5th Annual NASH Summit
CUPERTINO, Calif., Nov. 29, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced it will participate in a workshop today at the 5th Annual NASH Summit being held virtually from today through December 2, 2021. 
Nov 12, 2021 08:00 am ET
Data Presentation Today at The Liver Meeting® 2021 Shows Increasing Hospital Admissions for Alcohol-Associated Hepatitis (AH) in the U.S.
CUPERTINO, Calif., Nov. 12, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the presentation of data at the American Association for The Study of Liver Diseases (AASLD) The Liver Meeting® 2021 showcasing an increase of hospitalizations for alcohol-associated hepatitis (AH) in the U.S. of approximately 19% (from 110,085 in 2015 to 131,510 in 2018) or approximately 4.8% per year between 2015 and 2018.
Nov 10, 2021 08:00 am ET
DURECT Corporation Doses First ex-U.S. Patient in Phase 2b AHFIRM Study of Larsucosterol (DUR-928) in Severe Alcohol-Associated Hepatitis
CUPERTINO, Calif., Nov. 10, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it dosed the first ex-U.S. patient in Australia as part of its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to evaluate the safety and efficacy of larsucosterol in severe alcohol-associated hepatitis (AH) patients.
Nov 08, 2021 08:00 am ET
DURECT Corporation Announces Poster Presentation on the Prevalence of Hospitalized Alcohol-Associated Hepatitis (AH) Patients in the U.S. to be Presented at The Liver Meeting® 2021
CUPERTINO, Calif., Nov. 8, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Suthat Liangpunsakul, M.D. will present a poster at the American Association for The Study of Liver Diseases (AASLD) The Liver Meeting® 2021 to be held virtually November 12-15, 2021. 
Nov 02, 2021 04:05 pm ET
DURECT Corporation Reports Third Quarter 2021 Financial Results and Update of Programs
CUPERTINO, Calif., Nov. 2, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2021 and provided a corporate update.
Oct 26, 2021 09:00 am ET
DURECT Corporation to Announce Third Quarter 2021 Financial Results and Provide Business Update on November 2
CUPERTINO, Calif., Oct. 26, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its third quarter 2021 financial results and host a conference call after the market close on Tuesday, November 2, 2021.
Oct 07, 2021 09:00 am ET
DURECT Corporation Fireside Chat at the H.C. Wainwright 5th Annual NASH Investor Conference
CUPERTINO, Calif., Oct. 7, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman Sussman, Chief Medical Officer, and Dr. WeiQi Lin, Executive Vice President of R&D, will be participating in a fireside chat hosted by Ed Arce, Managing Director of Equity Research at H.C. Wainwright.
Sep 23, 2021 09:00 am ET
DURECT Corporation Fireside Chat at the Cantor Fitzgerald Global Healthcare Conference 2021
CUPERTINO, Calif., Sept. 23, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman Sussman, Chief Medical Officer, and Dr. WeiQi Lin, Executive Vice President of R&D, will be participating in a fireside chat hosted by Kristen Kluska, Director, Equity Research Analyst at Cantor Fitzgerald.
Sep 15, 2021 09:00 am ET
DURECT Corporation Fireside Chat at Oppenheimer's Fall Healthcare Life Sciences & MedTech Summit
CUPERTINO, Calif., Sept. 15, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman Sussman, Chief Medical Officer, and Dr. WeiQi Lin, Executive Vice President of R&D, will be participating in a fireside chat hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer & Co. Inc.
Sep 07, 2021 09:00 am ET
DURECT Corporation Fireside Chat at the H.C. Wainwright Annual Global Investment Conference
CUPERTINO, Calif., Sept. 7, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President, CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman Sussman, Chief Medical Officer and Dr. WeiQi Lin, Executive Vice President of R&D will be participating in a fireside chat hosted by Ed Arce of H.C. Wainwright, at the H.C. Wainwright 23rd Annual Global Investment Conference. A recording of the fireside chat will be available on-demand starting at 7:00 A.M. Eastern Standard Time on September 13, 2021. 
Jul 29, 2021 04:05 pm ET
DURECT Corporation Announces Second Quarter 2021 Financial Results and Update of Programs
CUPERTINO, Calif., July 29, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2021 and provided a corporate update.
Jul 22, 2021 08:30 am ET
DURECT Corporation to Announce Second Quarter 2021 Financial Results and Provide Business Update on July 29
CUPERTINO, Calif., July 22, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its second quarter 2021 financial results and host a conference call after the market close on Thursday, July 29, 2021.
Jul 14, 2021 04:30 pm ET
DURECT Corporation to Present at the 2021 Epigenetic Therapeutic Targets Virtual Summit
CUPERTINO, Calif., July 14, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it will present at the Epigenetic Therapeutic Targets Summit, being held virtually July 13-15, 2021. 
Jun 23, 2021 09:00 am ET
DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021 (EASL)
CUPERTINO, Calif., June 23, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the presentation of additional clinical data from a DUR-928 Phase 1b trial in non-alcoholic steatohepatitis (NASH) and a Phase 1 trial in subjects with hepatic impairment (HI) as part of two posters at the 2021 International Liver Conference (EASL) being held virtually June 23-26, 2021. 
Jun 09, 2021 09:00 am ET
DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL)
CUPERTINO, Calif., June 9, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it will present two posters at the 2021 International Liver Conference (EASL) to be held virtually June 23-26, 2021. 
Feb 25, 2021 03:05 pm ET
DURECT Corporation to Announce 2020 Financial Results and Provide Business Update on March 4
CUPERTINO, Calif., Feb. 25, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and year ended December 31, 2020 financial results and host a conference call after the market close on Thursday, March 4, 2021.
Feb 04, 2021 08:18 am ET
DURECT Corporation Announces Pricing of $42.5 Million Public Offering of Common Stock
CUPERTINO, Calif., Feb. 4, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program, today announced the pricing of its underwritten public offering of 17,708,333 shares of its common stock (the "Offering") for gross proceeds of approximately $42,500,000, before deducting the underwriting discounts and commissions and other estimated offering expenses payable
Feb 03, 2021 03:01 pm ET
DURECT Corporation Announces Proposed Offering of Common Stock
CUPERTINO, Calif., Feb. 3, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program, today announced that it is commencing an underwritten public offering of its common stock (the "Offering"). All of the shares to be sold in the Offering will be sold by DURECT, subject to customary closing conditions. In addition, DURECT intends to grant the underwriter for th
Feb 02, 2021 08:31 am ET
Thinking about buying stock in Durect Corp, T2 Biosystems, Gevo Inc, BioNano Genomics, or Advanced Micro Devices?
NEW YORK, Feb. 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DRRX, TTOO, GEVO, BNGO, and AMD.
Feb 02, 2021 07:01 am ET
DURECT Corporation Announces U.S. FDA Approval of POSIMIR® For Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression
CUPERTINO, Calif., Feb. 2, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration (FDA) has approved POSIMIR® (bupivacaine solution) for infiltration use in adults for administration into the subacromial space under direct arthroscopic visualization to produce post-surgical analgesia for up to 72 hours following arthroscopic subacromial decompression. The approval was based on positive data from a randomized, multicenter, assessor-blinded, placebo–controlled clinical trial in patients undergoing arthroscopic subacromial decompression
Jan 25, 2021 07:30 am ET
DURECT Corporation Announces First Patient Dosed in Phase 2b AHFIRM Study of DUR-928 in Severe Alcohol-Associated Hepatitis
CUPERTINO, Calif., Jan. 25, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has dosed the first patient in its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to evaluate the safety and efficacy of DUR-928 in severe alcohol-associated hepatitis (AH) patients.
Jan 05, 2021 07:30 am ET
DURECT Corporation Appoints Two New Board Members
CUPERTINO, Calif., Jan. 5, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the appointment of two new members to its board of directors, Gail J. Maderis, MBA and Mohammad Azab, M.D., M. Sc., MBA, two senior industry veterans with extensive drug development, clinical research and medical affairs experience.
Jan 04, 2021 07:30 am ET
DURECT Corporation Announces Closing of LACTEL® Absorbable Polymer Product Line Sale to Evonik and Receipt of $15 Million
CUPERTINO, Calif., Jan. 4, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the sale of the LACTEL product line to Evonik closed and the $15 million payment was received on December 31, 2020.
Dec 21, 2020 07:30 am ET
DURECT Corporation to Participate in Investor Conferences in January 2021
CUPERTINO, Calif., Dec. 21, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will participate in the forthcoming H.C. Wainwright BioConnect 2021 Conference and Annual LifeSci Advisors Corporate Access Event. Both conferences will take place virtually. 
Dec 16, 2020 07:30 am ET
DURECT Corporation Announces DUR-928 Granted FDA Fast Track Designation for Treatment of Alcoholic Hepatitis
CUPERTINO, Calif., Dec. 16, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to DUR-928 for the treatment of alcoholic hepatitis (AH, also known as alcohol-associated hepatitis). AH is an acute, life-threatening form of alcohol-associated liver disease (ALD). DUR-928 is the lead investigational product candidate in DURECT's Epigenetic Regulator program.  
Dec 07, 2020 10:15 am ET
DURECT Corporation to Sell its LACTEL® Absorbable Polymer Product Line to Evonik for $15 Million
CUPERTINO, Calif., Dec. 7, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has signed an agreement to sell its LACTEL Absorbable Polymer (LACTEL) product line to Evonik, a global leader in specialty chemicals.
Nov 13, 2020 08:00 am ET
DURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020
CUPERTINO, Calif., Nov. 13, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today presented additional safety data and efficacy signals from its Phase 1b clinical trial of DUR-928 in nonalcoholic steatohepatitis (NASH) patients in a poster presentation at The AASLD Liver Meeting Digital Experience ™ (TLMdX) 2020.
Nov 10, 2020 07:30 am ET
DURECT Corporation to Host Webinar on the Treatment of Alcoholic Hepatitis Featuring Chief Medical Officer Dr. Norman Sussman
CUPERTINO, Calif., Nov. 10, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Norman Sussman, MD, FAASLD, newly appointed Chief Medical Officer, will host a webinar on the treatment landscape and unmet medical need in treating patients with alcoholic hepatitis (AH), as well as information on DURECT' investigational drug candidate, DUR-928, being developed for the treatment of AH. The webinar will be held on Friday, November 20, 2020 at 1:00 pm Eastern Time.  Dr. Sussman will be available to answer questions following the formal presentations.
Nov 02, 2020 03:05 pm ET
DURECT Corporation Announces Third Quarter 2020 Financial Results and Update of Programs
CUPERTINO, Calif., Nov. 2, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2020 and provided a corporate update.
Nov 02, 2020 03:02 pm ET
DURECT Corporation Appoints Dr. Norman Sussman as Chief Medical Officer
CUPERTINO, Calif., Nov. 2, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on the development of treatments for acute organ injury and chronic liver diseases, today announced it has appointed Norman Sussman, M.D. as its Chief Medical Officer, effective immediately. In this new role, Dr. Sussman will oversee the clinical development of DURECT's pipeline including multiple indications for its lead investigational drug candidate DUR-928.
Oct 27, 2020 08:30 am ET
DURECT Corporation to Announce Third Quarter 2020 Financial Results and Provide Business Update on November 02, 2020
CUPERTINO, Calif., Oct. 27, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report third quarter 2020 financial results and host a conference call after the market close on Monday, November 2, 2020.
Oct 26, 2020 04:30 pm ET
DURECT Corporation to Participate in the ROTH Capital Partners Healthcare Event "Covid-19 Therapeutics in Development"
CUPERTINO, Calif., Oct. 26, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will partipate in the ROTH Capital Healthcare Event, "Covid-19 Therapeutics in Development," taking place on Wednesday, October 28, 2020.  The ROTH Healthcare and Biotechnology team are hosting the webinar to discuss key therapies in development to treat COVID disease. 
Aug 05, 2020 08:30 am ET
DURECT to Present at the BTIG Biotechnology Conference 2020
CUPERTINO, Calif., Aug. 5, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer and Dr. WeiQi Lin, Executive Vice President of R&D will be participating in a fireside chat at the BTIG Biotechnology Conference 2020, Monday, August 10, 2020 at 11:00 a.m. EDT / 8:00 a.m. PDT.  Institutional investors that are participating in the conference may request a virtual one-on-one meeting through the conference coordinators.
Aug 03, 2020 04:05 pm ET
DURECT Corporation Announces Second Quarter 2020 Financial Results and Update of Programs
CUPERTINO, Calif., Aug. 3, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2020 and provided a corporate update.
Jul 28, 2020 08:30 am ET
DURECT Corporation to Announce Second Quarter 2020 Financial Results and Provide Business Update on August 03
CUPERTINO, Calif., July 28, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report second quarter 2020 financial results and host a conference call after the market close on Monday, August 3, 2020.
Jul 01, 2020 08:30 am ET
DURECT Corporation Announces Initiation of Patient Recruitment in Phase 2 Safety and Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury
CUPERTINO, Calif., July 1, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has initiated recruiting patients for its randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the safety and efficacy of DUR-928 in hospitalized COVID-19 infected patients with acute liver or kidney injury. The primary efficacy endpoint is a composite of survival and being free of acute organ failure at Day 28. The trial will enroll approximately 80 patients.
Jun 29, 2020 08:30 am ET
DURECT Corporation Joins the Russell 3000® Index
CUPERTINO, Calif., June 29, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it is set to join the broad-market Russell 3000® Index as a result of the 2020 Russell indexes annual reconstitution, effective after the US stock market opens today, June 29, 2020.
Jun 26, 2020 05:15 pm ET
Gilead Terminates License Agreement for Long-Acting Injectable HIV Investigational Product
CUPERTINO, Calif., June 26, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Gilead Sciences, Inc., (Gilead) has provided notice that, effective as of December 22, 2020, it is terminating the License Agreement dated July 19, 2019 and a related R&D agreement between Gilead and DURECT related to the development and commercialization of a long-acting injectable HIV investigational product utilizing DURECT's SABER® technology.
May 28, 2020 09:00 am ET
DURECT to Present at the Jefferies 2020 Virtual Health Care Conference
CUPERTINO, Calif., May 28, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Jefferies 2020 Virtual Health Care Conference, Wednesday, June 3, 2020 at 10:00 a.m. EDT / 7:00 a.m. PDT.  Institutional investors and analysts that are participating in the conference may request a virtual one-on-one meeting through the conference coordinators.
May 26, 2020 08:30 am ET
DURECT Corporation Announces Positive Topline Data from Phase 1b Study of DUR-928 in NASH
CUPERTINO, Calif., May 26, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced positive topline results from its Phase 1b clinical study of orally administered DUR-928 in nonalcoholic steatohepatitis (NASH) patients.
May 11, 2020 04:05 pm ET
DURECT Corporation Announces First Quarter 2020 Financial Results and Update of Programs
CUPERTINO, Calif., May 11, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2020 and provided a corporate update.
May 04, 2020 05:00 pm ET
DURECT Corporation to Announce First Quarter 2020 Financial Results and Provide Business Update on May 11
CUPERTINO, Calif., May 4, 2020  DURECT Corporation (Nasdaq: DRRX) today announced that it will report first quarter 2020 financial results and host a conference call after the market close on Monday, May 11, 2020.
Nov 15, 2019 07:00 am ET
DURECT to Present at the Stifel 2019 Health Care Conference
CUPERTINO, Calif., Nov. 15, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Stifel 2019 Health Care Conference, at the Lotte New York Palace Hotel on Tuesday, November 19, 2019 at 3:35 p.m. EST.  Institutional investors and analysts that are attending the conference may request a one-on-one meeting through the conference coordinators.
Nov 12, 2019 07:45 am ET
DURECT Corporation Announces Positive Results from the Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis Patients in a Late-Breaking Presentation at The Liver Meeting®
CUPERTINO, Calif., Nov. 12, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in alcoholic hepatitis (AH), presented as a late-breaking oral presentation at The Liver Meeting®.  The study results were also selected for inclusion in the 'Best of The Liver Meeting' summary slide presentation in the alcohol-related liver disease category.  Today at Noon Eastern Time, DURECT will host a Key Opinion Leader (KOL) webcast featuring a presentation of the results delivered by one of the principal investigators of the trial,
Nov 06, 2019 04:47 pm ET
DURECT to Host Key Opinion Leader Call on DUR-928 Phase 2a Alcoholic Hepatitis Study Results
CUPERTINO, Calif., Nov. 6, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will host a key opinion leader (KOL) conference call and live webcast to discuss the results of its recently completed Phase 2a clinical trial of DUR-928 in patients with alcoholic hepatitis (AH) on Tuesday, November 12 at 12:00 noon EST. The call will feature a review of the late-breaking oral presentation that Tarek I. Hassanein, M.D. will deliver at The Liver Meeting® 2019 at 8:30 a.m. EST on Tuesday, November 12.
Nov 04, 2019 03:05 pm ET
DURECT Corporation Announces Third Quarter 2019 Financial Results and Update of Programs
CUPERTINO, Calif., Nov. 4, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2019 and provided a corporate update.
Oct 30, 2019 08:00 am ET
DURECT Corporation to Announce Third Quarter 2019 Financial Results and Provide Business Update on November 4
CUPERTINO, Calif., Oct. 30, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report third quarter and nine months ended September 30, 2019 financial results and host a conference call after the market close on Monday, November 4, 2019.
Oct 21, 2019 10:12 am ET
DURECT Announces DUR-928 Phase 2a Alcoholic Hepatitis Study Results Selected for Late-Breaking Oral Presentation at The Liver Meeting® 2019
CUPERTINO, Calif., Oct. 21, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the results from the recently completed Phase 2a study of DUR-928 in patients with alcoholic hepatitis (AH) have been selected for an oral presentation as part of the late-breaking session of The Liver Meeting® 2019, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), taking place on November 8-12, 2019, in Boston. This late-breaking abstract was one of only 29 late-breaking abstracts selected out of a total of approximately 3,000 abstracts that were acc
Oct 17, 2019 04:05 pm ET
DURECT to Present at Two Upcoming NASH Investor Conferences
CUPERTINO, Calif., Oct. 17, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will be presenting at two upcoming investor conferences focused on non-alcoholic steatohepatitis (NASH): the H.C. Wainwright 3rd Annual NASH Investor Conference, to be held in New York City on Monday, October 21, 2019 and the B. Riley "NASH-ing in, Let's All Dig in on What's to Come at AASLD'19 and EASL'20" NASH symposium, to be held in San Francisco on Thursday, October 24, 2019.
Oct 07, 2019 08:00 am ET
DURECT Announces Completion of Enrollment in its Phase 2a Clinical Trial of DUR-928 in Psoriasis and 50% Enrollment in its Phase 1b DUR-928 Clinical Trial in NASH
CUPERTINO, Calif., Oct. 7, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has completed enrollment in its Phase 2a clinical trial of topical DUR-928 in patients with mild to moderate plaque psoriasis. The company also announced that it has now enrolled 30 of the planned 60 patients in its ongoing Phase 1b trial with oral DUR-928 in patients with non-alcoholic steatohepatitis (NASH).
Oct 02, 2019 08:00 am ET
DURECT Announces FDA Advisory Committee Meeting to Review POSIMIR® for the Treatment of Post-Surgical Pain
CUPERTINO, Calif., Oct. 2, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the U.S. Food and Drug Administration (FDA) has notified the Company that its Class 2 NDA resubmission for POSIMIR® (bupivacaine extended-release solution) will be discussed at a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC). The meeting is tentatively scheduled for January 16, 2020. The FDA had previously assigned a user fee goal date of December 27, 2019; a new user fee goal date has not been assigned.
Sep 26, 2019 08:00 am ET
DURECT to Present at the 2019 Cantor Fitzgerald Global Health Care Conference
CUPERTINO, Calif., Sept. 26, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, Chief Executive Officer will be presenting at the Cantor Fitzgerald Global Health Care Conference, at the InterContinental New York Barclay Hotel on Friday, October 4, 2019 at 10:40 a.m. EDT.  Institutional investors and analysts that are attending the conference may request a one-on-one meeting through the conference coordinators.
Sep 17, 2019 08:00 am ET
DURECT Announces Positive Data from its Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis
CUPERTINO, Calif., Sept. 17, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has completed the Phase 2a clinical trial of its lead product candidate, DUR-928, in patients with alcoholic hepatitis (AH). The final enrollment for the trial consists of 12 severe patients (MELD 21-30) and 7 moderate patients (MELD 11-20) for a total of 19 AH patients.
Sep 09, 2019 09:29 am ET
DURECT Earns $10 Million Milestone Payment for Further Development of a Long-Acting Injectable HIV Investigational Product Utilizing DURECT's SABER® Technology
CUPERTINO, Calif., Sept. 9, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that further development of a long-acting injectable HIV investigational product utilizing DURECT's SABER® technology has triggered a $10 million milestone payment from Gilead Sciences, Inc. to DURECT under the license agreement between the companies.
Sep 04, 2019 08:00 am ET
DURECT to Present at the 21st Annual Rodman and Renshaw Global Investment Conference Sponsored by H.C. Wainwright
CUPERTINO, Calif., Sept. 4, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, Chief Executive Officer will be presenting at the 21st Annual Global Rodman and Renshaw Investment Conference, sponsored by H. C. Wainwright, at the Lotte New York Palace Hotel in New York on Monday, September 9, 2019 at 11:40 a.m. EDT.  Institutional investors and analysts that are attending the conference may request a one-on-one meeting through the conference coordinators.
Aug 01, 2019 04:05 pm ET
DURECT Corporation Announces Second Quarter 2019 Financial Results and Update of Programs
CUPERTINO, Calif., Aug. 1, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2019 and provided a corporate update.
Jul 25, 2019 04:30 pm ET
DURECT Corporation to Announce Second Quarter 2019 Financial Results on August 1
CUPERTINO, Calif., July 25, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report second quarter and six months ended June 30, 2019 financial results and host a conference call after the market close on Thursday, August 1, 2019.
Jul 22, 2019 08:00 am ET
DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product
CUPERTINO, Calif., July 22, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into an agreement with Gilead Sciences, Inc. granting Gilead the exclusive worldwide rights to develop and commercialize a long-acting injectable HIV product utilizing DURECT's SABER® technology.  Gilead also received exclusive access to the SABER® platform for HIV and Hepatitis B Virus (HBV) and the exclusive option to license additional SABER-based products directed to HIV and HBV.
Jul 17, 2019 08:00 am ET
DURECT Announces that the FDA Agreed to File the Full Response to the POSIMIR® Complete Response Letter as a Complete Class 2 Resubmission
CUPERTINO, Calif., July 17, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged that the submission of DURECT's full response to the Complete Response Letter (CRL) it previously received from FDA related to POSIMIR® (bupivacaine extended-release solution) is considered by the FDA to be a complete class 2 response to the CRL. The user fee goal date is December 27, 2019.  The submission is intended to address the issues raised in the CRL and seeks FDA approval of POSIMIR based on what the Company and its advis
May 16, 2019 04:15 pm ET
DURECT to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019
CUPERTINO, Calif., May 16, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, Chief Executive Officer, and Michael H. Arenberg, Chief Financial Officer, will be participating in the 20th Annual B. Riley FBR Institutional Investor Conference, taking place at the Beverly Hilton Hotel, Beverly Hills, CA May 22-23.
May 07, 2019 09:03 pm ET
DURECT Corporation Announces Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial
CUPERTINO, Calif., May 7, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced preliminary data from the ongoing DUR-928 alcoholic hepatitis (AH) Phase 2a clinical trial.  On Wednesday, May 8th at 8:30 a.m. Eastern Time, DURECT will host a Key Opinion Leader (KOL) and earnings conference call, during which the Company will discuss financial results for the first quarter of 2019, provide a corporate business update, and present preliminary AH clinical trial data via webcast. Also participating in the call will be three KOLs on alcoholic hepatitis: Drs. Steven Flamm, Tarek Ha
May 07, 2019 05:42 pm ET
DURECT Corporation Announces First Quarter 2019 Financial Results and Update of Programs
CUPERTINO, Calif., May 7, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2019 and provided a corporate update, including preliminary data from the ongoing DUR-928 Phase 2a alcoholic hepatitis (AH) trial.
May 03, 2019 01:26 pm ET
DURECT Corporation to Present Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial and Report First Quarter 2019 Financial Results
CUPERTINO, Calif., May 3, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report preliminary data from the ongoing DUR-928 alcoholic hepatitis (AH) trial and its financial results for the three months ended March 31, 2019 after the market close on Tuesday, May 7. The following morning, Wednesday, May 8th at 8:30 a.m. Eastern Time, DURECT will host a Key Opinion Leader (KOL) and earnings conference call and webcast with slides.
Apr 25, 2019 08:00 am ET
DURECT Appoints Two New Board Members
CUPERTINO, Calif., April 25, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today the appointment of two new members to its board of directors.  Dr. Gail M. Farfel, Executive Vice President and Chief Development Officer of Zogenix, Inc., and Judith J. Robertson, most recently Chief Commercial Officer of Aerie Pharmaceuticals, bring to DURECT extensive product development, regulatory and commercialization experience.
Apr 10, 2019 07:25 am ET
Analysis: Positioning to Benefit within The Allstate, Seattle Genetics, Intra-Cellular Therapies, AMN Healthcare Services, AVX, and DURECT — Research Highlights Growth, Revenue, and Consolidated Resul
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Allstate Corporation (NYSE:ALL), Seattle Genetics, Inc. (NASDAQ:SGEN),...
Apr 01, 2019 08:00 am ET
DURECT to Present at the H.C. Wainwright Global Life Sciences Conference and Host an Upcoming KOL call on NASH
CUPERTINO, Calif., April 1, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Michael Arenberg, Chief Financial Officer, will be presenting at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 9 at 10:50 a.m. BST / 05.50 a.m. EDT.  The conference is being held at the JW Marriott Grosvenor House in London.  Institutional investors and analysts that are attending the conference may request a one-on-one meeting through the conference coordinators.
Mar 27, 2019 08:00 am ET
DURECT Announces Patient Enrollment in Phase 1b Clinical Trial of Oral DUR-928 in Patients with Non-Alcoholic Steatohepatitis (NASH)
CUPERTINO, Calif., March 27, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient enrollment in a Phase 1b trial with oral DUR-928 in patients with NASH.  DUR-928, the lead investigational product in the Company's Epigenetic Regulator Program, is an endogenous, first-in-class small molecule, which may have broad applicability in chronic hepatic diseases such as NASH, acute organ injuries such as alcoholic hepatitis (AH) and acute kidney injury (AKI), and in inflammatory skin disorders such as psoriasis and atopic dermatitis.
Mar 21, 2019 08:00 am ET
DURECT Announces Patient Dosing in Phase 2a Proof-of-Concept Clinical Trial of Topical DUR-928 in Patients with Mild to Moderate Plaque Psoriasis
CUPERTINO, Calif., March 21, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient dosing in a Phase 2a proof-of-concept trial with topical DUR-928 in patients with mild to moderate plaque psoriasis.  DUR-928, the lead investigational product in the Company's Epigenetic Regulator Program, is an endogenous, first-in-class small molecule, which may have broad applicability in chronic hepatic diseases such as nonalcoholic steatohepatitis (NASH), acute organ injuries such as alcoholic hepatitis (AH) and acute kidney injury (AKI), and in inflammatory skin
Mar 07, 2019 03:05 pm ET
DURECT Corporation Announces Fourth Quarter and Full Year 2018 Financial Results and Update of Programs
CUPERTINO, Calif., March 7, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2018 and provided a corporate update.  
Mar 04, 2019 07:00 am ET
DURECT Corporation Invites You to Join its Fourth Quarter 2018 Earnings Conference Call
CUPERTINO, Calif., March 4, 2019 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2018 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Thursday, March 7, 2019 at 4:30 pm Eastern Time (1:30 pm Pacific Time).
Feb 27, 2019 06:00 am ET
DURECT Announces Plans to Submit to FDA a Full Response to the POSIMIR® Complete Response Letter
CUPERTINO, Calif., Feb. 27, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has completed a comprehensive review of its POSIMIR® (bupivacaine extended-release solution) program and plans to submit a full response to the Complete Response Letter (CRL) it previously received from U.S. Food and Drug Administration (FDA).  The submission will request FDA approval of POSIMIR based on what the Company and its advisors believe is adequate evidence of both safety and efficacy.
Feb 22, 2019 07:20 am ET
Factors of Influence in 2019, Key Indicators and Opportunity within ARRIS International plc, Edwards Lifesciences, DENTSPLY SIRONA, Vail Resorts, Akers Biosciences, and DURECT — New Research Emphasize
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ARRIS International plc (NASDAQ:ARRS), Edwards Lifesciences Corporation...
Feb 21, 2019 07:00 am ET
DURECT Corporation to Participate in the Berenberg NASH Day
CUPERTINO, Calif., Feb. 21, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and CEO, and Mike Arenberg, Chief Financial Officer, will be participating in the Berenberg NASH Day, taking place Tuesday, February 26, 2019, at Berenberg's New York City offices.  The format for the day includes an introductory session, a presentation by Dr. Raymond Chung of Harvard Medical School, a five minute presentation by DURECT management and other attending companies, and then one-on-one/small group meetings with companies and with key opinion leaders (D
Jan 07, 2019 06:30 am ET
DURECT Corporation Provides Corporate Update
CUPERTINO, Calif., Jan. 7, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) has refined and focused its clinical development strategy for DUR-928, the lead product candidate in its Epigenetic Regulator Program, to prioritize indications with unmet medical needs where we expect to be able to generate near-term data with the potential to create significant commercial and partnering value. The new DUR-928 clinical development strategy is:
Jan 03, 2019 03:30 pm ET
DURECT Corporation Announces Investor Call to Provide Corporate Update
CUPERTINO, Calif., Jan. 3, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) invites interested parties to listen to a corporate update conference call that will be broadcast live over the internet on Monday, January 7, 2019 at 8:00 am Eastern Time (5:00 am Pacific Time).
Dec 19, 2018 07:00 am ET
Commercial Launch Plans Announced for PERSERIS™ (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
CUPERTINO, Calif., Dec. 19, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Indivior PLC (LON: INDV) stated on December 18, 2018 that it is moving ahead with the launch of PERSERIS™ in the U.S. with a sales force consisting of approximately 50 representatives. While PERSERIS™ has been available in the U.S. since November 19, 2018, Indivior stated that the commercial launch is scheduled to take place in February 2019. Indivior stated that its PERSERIS™ team is currently engaged in creating payor access, growing prescriber awareness and interest, as well as establis
Dec 17, 2018 07:00 am ET
DURECT Corporation Announces Retirement of Dr. Felix Theeuwes as Chairman of the Board and Distinguished Scientist
CUPERTINO, Calif., Dec. 17, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Felix Theeuwes will retire as Chairman of the Board and Distinguished Scientist effective December 31, 2018.  Dr. Theeuwes has been scaling back his activities in recent years, having gone to three days per week in April 2015 and one day per week in February 2018.  David R. Hoffmann will assume the role of Chairman of the Board; he had been Lead Independent Director of the Board and will continue as Chairman of the Audit Committee.  In addition, the Board of Directors has initiated a searc
Nov 30, 2018 07:55 am ET
Analysis: Positioning to Benefit within News Corporation, DURECT, Ecolab, MiX Telematics, Ship Finance International, and BCE — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of News Corporation (NASDAQ:NWS), DURECT Corporation (NASDAQ:DRRX), Ecolab...
Nov 19, 2018 07:00 am ET
DURECT Announces Amendment to Accelerate Ongoing Phase 2a Trial of DUR-928 in Alcoholic Hepatitis (AH) by Allowing Dosing of Severe AH Patients in Parallel to Moderate AH Patients
CUPERTINO, Calif., Nov. 19, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has amended its ongoing Phase 2a clinical trial of intravenously administered DUR-928 in patients with alcoholic hepatitis (AH) to accelerate the initiation of dosing of severe AH patents.  The Company recently completed dosing for the low-dose 30 mg cohort (n=4) of Part A (moderate AH patients), and with this amendment in place, can now begin enrolling Part B (severe AH patients), starting with the low dose, while it simultaneously continues enrolling Part A at the next higher dose (90 mg).
Nov 07, 2018 03:01 pm ET
DURECT Corporation Announces Third Quarter 2018 Financial Results and Provides Corporate Update
CUPERTINO, Calif., Nov. 7, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2018 and provided a corporate update.  
Nov 01, 2018 04:15 pm ET
DURECT Corporation Invites You to Join its Third Quarter 2018 Earnings Conference Call
CUPERTINO, Calif., Nov. 1, 2018 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2018 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Wednesday, November 7, 2018 at 4:30 pm Eastern Time (1:30 pm Pacific Time).
Oct 25, 2018 08:00 am ET
DURECT Announces Abstracts on DUR-928 to be Presented at Upcoming Scientific Meetings
CUPERTINO, Calif., Oct. 25, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that two posters on DUR-928 will be presented at the ASN Kidney Week Meeting on Saturday, October 27 and one poster will be presented at the American College of Toxicology's Annual Meeting, November 4-7. DUR‑928, a new chemical entity in Phase 2 development, is the lead candidate in DURECT's Epigenetic Regulator Program. An endogenous small molecule, DUR-928 has been shown in preclinical studies to play an important regulatory role in lipid homeostasis, inflammation, and cell survival.
Oct 23, 2018 08:20 am ET
Report: Exploring Fundamental Drivers Behind Alder BioPharmaceuticals, DURECT, Mettler-Toledo International, Internap, Career Education, and Approach Resources — New Horizons, Emerging Trends, and Upc
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), DURECT Corporation...
Oct 01, 2018 08:00 am ET
DURECT Corporation Appoints Michael H. Arenberg, J.D., M.B.A. as Chief Financial Officer
CUPERTINO, Calif., Oct. 1, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today the appointment of Michael H. Arenberg to the position of Chief Financial Officer, effective October 15, 2018. Mr. Arenberg will be responsible for overseeing all financial and capital market activities at DURECT, including accounting, financial reporting, financial planning and analysis, and investor relations. DURECT has entered into a consulting arrangement through April 15, 2019 with outgoing Chief Financial Officer, Matthew J. Hogan, to provide support and facilitate the transition. 
Sep 25, 2018 08:00 am ET
DURECT to Present at the Cantor Fitzgerald Global Healthcare Conference
CUPERTINO, Calif., Sept. 25, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, October 3 at 1:40 p.m. Eastern Time.  The conference is being held at the InterContinental New York Barclay hotel in New York City.  Institutional investors and analysts that are attending the conference may request a one-on-one meeting through the conference coordinators.
Sep 18, 2018 08:00 am ET
DURECT Announces Methydur Sustained Release Capsules Receive Marketing Authorization for ADHD in Taiwan
CUPERTINO, Calif., Sept. 18, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Orient Pharma Co., Ltd., its licensee for certain Asian and South Pacific countries, has informed DURECT that it has obtained marketing authorization from the Ministry of Health and Welfare in Taiwan for Methydur Sustained Release Capsules.  Methydur Sustained Release Capsules are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and will be available in three strengths (22 mg, 33 mg and 44 mg) in Taiwan.  Orient Pharma also has stated that it expects to have
Aug 30, 2018 08:00 am ET
DURECT Announces Receipt of $5 Million Milestone Payment from Indivior
CUPERTINO, Calif., Aug. 30, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has received a $5 million milestone payment from Indivior PLC (LON: INDV), triggered by Indivior's approval of the New Drug Application (NDA) for PERSERIS™ (risperidone) in July 2018. 
Aug 27, 2018 04:30 pm ET
DURECT to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
CUPERTINO, Calif., Aug. 27, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., on Thursday, September 6 at 9:10 a.m. Eastern Time.  The conference is being held at the St. Regis Hotel in New York City.  Institutional investors and analysts that are attending the conference may request a one-on-one meeting through the conference coordinators.
Aug 21, 2018 07:45 am ET
Recent Analysis Shows DURECT, Corporacion America Airports S.A., Golden Star Resources, MacroGenics, Merus N.V., and Superior Uniform Group Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of DURECT Corporation (NASDAQ:DRRX), Corporacion America Airports S.A....
Aug 06, 2018 09:22 am ET
DURECT's Licensee Pain Therapeutics Receives Complete Response Letter from FDA for REMOXY® ER (oxycodone) Extended-Release Capsules CII
CUPERTINO, Calif., Aug. 6, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) reported that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for Pain Therapeutics' New Drug Application (NDA) for REMOXY® ER (oxycodone) extended-release capsules CII, which concluded that "The data submitted in [the] NDA do not support the conclusion that the benefits of [REMOXY] Extended-Release Capsules outweigh the risks."  Pain Therapeutics further announced a strategic reorganization to align its
Aug 01, 2018 04:05 pm ET
DURECT Corporation Announces Second Quarter 2018 Financial Results and Provides Corporate Update
CUPERTINO, Calif., Aug. 1, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2018 and provided a corporate update.  
Jul 30, 2018 08:00 am ET
DURECT Announces FDA Approval of Indivior's PERSERIS™ (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
CUPERTINO, Calif., July 30, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Indivior PLC (LON: INDV) has reported that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for PERSERIS™ (risperidone), which was formerly known as RBP-7000.  As described by Indivior, PERSERIS is the first once-monthly subcutaneous risperidone-containing, long-acting injectable for the treatment of schizophrenia in adults.   
Jul 24, 2018 04:05 pm ET
DURECT Corporation Invites You to Join its Second Quarter 2018 Earnings Conference Call
CUPERTINO, Calif., July 24, 2018 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2018 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Wednesday, August 1, 2018 at 4:30 pm Eastern Time (1:30 pm Pacific Time).
Jun 26, 2018 08:30 pm ET
Results of FDA Advisory Committee Meeting for REMOXY® ER
CUPERTINO, Calif., June 26, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today reported that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 14 to 3 against the approval of REMOXY® ER (oxycodone extended-release capsules) for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.  The development and commercialization rights of REMOXY ER ar
Jun 07, 2018 08:10 am ET
New Research Coverage Highlights Durect, Credit Suisse Group, Obsidian Energy, TransCanada, Golden Star Resources, and Loxo Oncology — Consolidated Revenues, Company Growth, and Expectations for 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Durect Corporation (NASDAQ:DRRX), Credit Suisse Group (NYSE:CS), Obsidian...
May 09, 2018 08:00 am ET
DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR® (SABER®-Bupivacaine)
CUPERTINO, Calif., May 9, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has entered into an amendment (the "Amendment") to the development and commercialization agreement with Sandoz AG, a division of Novartis (NYSE: NVS), regarding POSIMIR® (SABER®-bupivacaine) in the United States.  
May 02, 2018 04:05 pm ET
DURECT Corporation Announces First Quarter 2018 Financial Results and Provides Corporate Update
CUPERTINO, Calif., May 2, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2018 and provided a corporate update.  
Apr 25, 2018 08:00 am ET
DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Alcoholic Hepatitis
CUPERTINO, Calif., April 25, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient dosing in a Phase 2a clinical trial of DUR-928 in patients with alcoholic hepatitis (AH).  DUR-928, the lead investigational product in our Epigenetic Regulator Program, is an endogenous, first-in-class small molecule, which may have broad applicability in diseases such as nonalcoholic steatohepatitis (NASH) and other disorders of the liver such as PSC, in acute organ injuries such as acute liver and kidney injury, and in inflammatory skin disorders such as psoriasis a
Apr 24, 2018 04:30 pm ET
DURECT Corporation Invites You to Join its First Quarter 2018 Earnings Conference Call
CUPERTINO, Calif., April 24, 2018 /PRNewswire/ -- In conjunction with DURECT Corporation's(Nasdaq: DRRX) first quarter 2018 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Wednesday, May 2, 2018 at 4:30 pm Eastern Time (1:30 pm Pacific Time).
Mar 29, 2018 08:00 am ET
DURECT Corporation to Host Key Opinion Leader Call on Alcoholic Hepatitis
CUPERTINO, Calif., March 29, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it will host a key opinion leader (KOL) call on the treatment of alcoholic hepatitis (AH) on Thursday, April 5 at 11:00 a.m. Eastern Time.
Mar 26, 2018 07:40 am ET
Investor Expectations to Drive Momentum within Aon plc, Endeavour Silver, BlackBerry, DURECT, Castle Brands, and Nabors Industries — Discovering Underlying Factors of Influence
NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aon plc (NYSE:AON), Endeavour Silver Corporation...
Mar 20, 2018 08:00 am ET
DURECT Announces FDA Advisory Committee Meeting for REMOXY® ER
CUPERTINO, Calif., March 20, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE), reported yesterday that the U.S. Food and Drug Administration (FDA) will hold an Advisory Committee Meeting to discuss the New Drug Application (NDA) for REMOXY ER (extended release oxycodone CII).  REMOXY® ER is designed as an abuse-deterrent, extended release, capsule formulation of oxycodone, a prescription drug for severe pain.  The tentative date for the Advisory Committee Meeting is June 26, 2018.  The Prescription Drug User Fee Act (P
Mar 01, 2018 03:05 pm ET
DURECT Corporation Announces Fourth Quarter and Full Year 2017 Financial Results and Update of Programs
CUPERTINO, Calif., March 1, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2017 and provided a corporate update.  
Feb 26, 2018 07:00 am ET
DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis (PSC)
CUPERTINO, Calif., Feb. 26, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient dosing in a Phase 2a clinical trial of DUR-928 in patients with primary sclerosing cholangitis (PSC).  DUR-928, the lead investigational product in our Epigenetic Regulator Program, is an endogenous, first-in-class small molecule, which may have broad applicability in several hepatic and renal diseases such as nonalcoholic steatohepatitis (NASH) and other disorders of the liver such as PSC, in acute organ injuries such as acute liver and kidney injury, and in inflammato
Feb 22, 2018 03:30 pm ET
DURECT Corporation Invites You to Join its Fourth Quarter 2017 Earnings Conference Call
CUPERTINO, Calif., Feb. 22, 2018 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2017 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Thursday, March 1, 2018 at 4:30 pm Eastern Time (1:30 pm Pacific Time).
Feb 20, 2018 07:00 am ET
DURECT Corporation to Host Key Opinion Leader Call on Treatment of Primary Sclerosing Cholangitis (PSC)
CUPERTINO, Calif., Feb. 20, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it will host a key opinion leader (KOL) call on the treatment of primary sclerosing cholangitis (PSC) on Monday, February 26 at 12:00 p.m. Eastern Time.
Feb 14, 2018 07:00 am ET
DURECT Announces Resubmission of REMOXY® ER New Drug Application by its licensee, Pain Therapeutics
CUPERTINO, Calif., Feb. 14, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE), reported yesterday that it has resubmitted the New Drug Application (NDA) for REMOXY® ER to the U.S. Food and Drug Administration (FDA).  REMOXY ER is designed as an abuse-deterrent, extended release, capsule formulation of oxycodone, a prescription drug for severe pain.  Pain Therapeutics stated that it expects a six-month review cycle by FDA, and that it expects to be notified by FDA of a Prescription Drug User Fee Act (PDUFA) date within 6
Dec 13, 2017 07:00 am ET
DURECT Announces NDA Acceptance of Indivior's RBP-7000 Risperidone Monthly Depot
CUPERTINO, Calif., Dec. 13, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Indivior PLC (LON: INDV) has reported that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for RBP-7000.  RBP-7000 is an investigational, once-monthly injectable risperidone for the treatment of schizophrenia. Indivior PLC further reported that the FDA has set a PDUFA (Prescription Drug User Fee Act) target action date of July 28, 2018.
Nov 01, 2017 05:05 pm ET
DURECT Corporation Announces Third Quarter 2017 Financial Results and Provides Corporate Update
CUPERTINO, Calif., Nov. 1, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2017 and provided a corporate update.  
Oct 26, 2017 05:54 pm ET
DURECT Corporation Invites You to Join its Third Quarter 2017 Earnings Conference Call
CUPERTINO, Calif., Oct. 26, 2017 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2017 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Wednesday, November 1, 2017 at 4:30 pm Eastern Time (1:30 pm Pacific Time).
Oct 19, 2017 06:57 pm ET
DURECT Announces Top-line Results from the PERSIST Phase 3 Trial of POSIMIR® (SABER®-Bupivacaine) Did Not Meet Primary Efficacy Endpoint
CUPERTINO, Calif., Oct. 19, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today reported that PERSIST, the Phase 3 clinical trial for POSIMIR® (SABER®-Bupivacaine), did not meet its primary efficacy endpoint of reduction in pain on movement over the first 48 hours after surgery as compared to standard bupivacaine HCl.  While results trended in favor of POSIMIR versus the comparator, they did not achieve statistical significance.  POSIMIR is an investigational drug candidate being developed for the treatment of post-surgical pain.
Oct 05, 2017 08:45 am ET
Streetwise Reports Examines Small Biotech That Entered Patent Deal with British Company Targeting Schizophrenia
A small-cap American biotech has secured a patent agreement with a larger British firm, garnering the attention of three sector analysts.Included in this article is: DURECT Corp. (NASDAQ: DRRX)In an Oct. 2 press release, DURECT Corp. announced "a...
Oct 02, 2017 03:05 am ET
DURECT and Indivior PLC Sign a $17.5 Million Patent Purchase Agreement
CUPERTINO, Calif., Oct. 2, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced a patent purchase agreement with Indivior UK Limited, an affiliate of Indivior PLC (LON: INDV), whereby DURECT has assigned certain of its U.S. patent rights to Indivior. This assignment may provide further intellectual property protection for RBP-7000, Indivior's investigational once-monthly injectable risperidone product for the treatment of schizophrenia.  Indivior today announced that it has submitted a New Drug Application (NDA) for RBP-7000 to the U.S. Food and Drug Administration (FDA).
Sep 20, 2017 09:00 am ET
DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development
CUPERTINO, Calif., Sept. 20, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Myriam Theeuwes has joined DURECT as Senior Vice President, Clinical Development.  Dr. Theeuwes joins DURECT from Johnson & Johnson where she spent 18 years, most recently as Compound Development Team Leader for Janssen Pharmaceutical's global public health initiatives where she led the development and launch of products including SIRTURO® (bedaquiline), the first drug with a new mechanism of action to treat tuberculosis in over 40 years.  Since its original FDA approval in 2012,
Sep 05, 2017 05:15 pm ET
DURECT to Participate in Upcoming Healthcare Conferences
CUPERTINO, Calif., Sept. 5, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming investment conferences. 
Aug 08, 2017 05:05 pm ET
DURECT Corporation Announces Second Quarter 2017 Financial Results and Provides Corporate Update
CUPERTINO, Calif., Aug. 8, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2017 and provided a corporate update.  
Aug 08, 2017 09:30 am ET
ORADUR®-Methylphenidate ER Capsule Achieves Primary Endpoint in Phase 3 Study in ADHD in Taiwan
CUPERTINO, Calif., Aug. 8, 2017 /PRNewswire/-- DURECT Corporation (Nasdaq: DRRX) today announced that Orient Pharma Co., Ltd., its licensee for certain Asian and South Pacific countries, has informed DURECT that a Phase 3 clinical study of ORADUR-Methylphenidate ER Capsule conducted in Taiwan has achieved positive results.  ORADUR-Methylphenidate ER Capsule is an investigational drug candidate for the treatment of attention deficit hyperactivity disorder (ADHD).
Aug 01, 2017 05:15 pm ET
DURECT Corporation Invites You to Join its Second Quarter 2017 Earnings Conference Call
CUPERTINO, Calif., Aug. 1, 2017 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2017 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Tuesday, August 8, 2017 at 4:30 pm Eastern Time (1:30 pm Pacific Time).
Jul 20, 2017 08:45 am ET
Streetwise Reports Examines How Progress in Pain Control and Liver Disease Programs Spurs Rise in DURECT Corp.'s Rating
News about progress in two of this biotech's development programs prompted a rating upgrade by analyst Adam Walsh of Stifel Nicolaus & Company.Included in this article is: DURECT Corp. (NASDAQ: DRRX)In a July 12 research report, Stifel outlined...
Jul 06, 2017 08:45 am ET
Streetwise Reports Examines How Analysts Take Note as a Small-Cap Biotech Completes Early Enrollment for Phase 3 Trial
With enrollment complete in its Phase 3 trial of a compound that treats post-operative pain, and an infusion of cash from a new partnership with a major pharmaceutical corporation, one analyst has initiated coverage of this California-based company,...
Jun 22, 2017 08:00 am ET
DURECT Completes Enrollment in PERSIST, Phase 3 trial for POSIMIR®
CUPERTINO, Calif., June 22, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that patient enrollment has been completed in PERSIST, the pivotal Phase 3 clinical trial of POSIMIR® (SABER®-Bupivacaine), an investigational locally acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery.
Jun 19, 2017 08:00 am ET
DURECT's Collaboration with Sandoz Clears HSR Review and is Effective
CUPERTINO, Calif., June 19, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the previously disclosed development and commercialization agreement with Sandoz AG, a division of Novartis (NYSE: NVS), to develop and market in the United States DURECT's POSIMIR® (SABER®-Bupivacaine), an investigational locally acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery, has cleared review under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 and has become effective.
May 25, 2017 08:45 am ET
The Life Sciences Report Interviews H.C. Wainwright Analyst Ed Arce
NASH is an epidemic in the U.S., with more than 100 million people believed to be affected. Yet no FDA-approved treatments are available, with the exception of liver transplantation for end-stage disease. In part two of his interview with The Life...
May 11, 2017 08:45 am ET
The Life Sciences Report Examines DURECT and Sandoz's $293 Million Deal for POSIMIR
DURECT Corp. (NASDAQ: DRRX) and Sandoz AG, a division of Novartis, have signed a development and commercialization agreement for the U.S. for POSIMIR.Included in this article is: DURECT Corp.POSIMIR is DURECT Corp.'s "locally acting, non-opioid...
May 10, 2017 05:05 pm ET
DURECT Corporation Announces First Quarter 2017 Financial Results and Provides Corporate Update
CUPERTINO, Calif., May 10, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2017 and provided a corporate update.  
May 08, 2017 08:00 am ET
DURECT and Sandoz have Signed a $293 Million Development and Commercialization Agreement for POSIMIR® (SABER®-Bupivacaine) Covering the United States
CUPERTINO, Calif., May 8, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced a development and commercialization agreement with Sandoz AG, a division of Novartis (NYSE: NVS), to develop and market in the United States DURECT's POSIMIR® (SABER®-Bupivacaine), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery.
May 04, 2017 05:30 pm ET
DURECT Corporation Invites You to Join its First Quarter 2017 Earnings Conference Call
CUPERTINO, Calif., May 4, 2017 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2017 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Wednesday, May 10, 2017 at 4:30 pm Eastern Time (1:30 pm Pacific Time).
Apr 27, 2017 08:45 am ET
The Life Sciences Report Examines How Trial Results Set Up DURECT Corp. for 'Exciting Year'
Positive results in a Phase 1b trial of DURECT Corp.'s (NASDAQ: DRRX) candidate for the treatment of nonalcoholic steatohepatitis (NASH), which were presented at the 2017 International Liver Congress, prompted comments from a pair of...
Apr 24, 2017 09:00 am ET
DURECT Announces Presentation of Data from a Phase 1b Study of DUR-928 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017
CUPERTINO, Calif., April 24, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company actively developing new therapeutics based on its Epigenetic Regulator Program and proprietary drug delivery platforms, announced that clinical data on DUR-928 were presented at The International Liver CongressTM 2017 (the 52nd annual meeting of the European Association for the Study of the Liver (EASL)) on April 22 in Amsterdam.    
Apr 17, 2017 09:00 am ET
DURECT to Present Clinical Data at the International Liver Congress™ 2017
CUPERTINO, Calif., April 17, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company actively developing new therapeutics based on its Epigenetic Regulator Program and proprietary drug delivery platforms, announced today that it will present clinical data on DUR-928 at the International Liver Congress 2017 (the 52nd annual meeting of the European Association for the Study of the Liver (EASL)), which will be held April 19-23 in Amsterdam.    
Apr 03, 2017 08:30 am ET
DURECT to Present at the H.C. Wainwright NASH Investor Conference
CUPERTINO, Calif., April 3, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Jim Brown, President and Chief Executive Officer, will be presenting at the H.C. Wainwright NASH Investor Conference on Monday, April 3  at 4:40 p.m. Eastern Time.  The conference is being held at the St. Regis Hotel in New York City. 
Mar 30, 2017 08:45 am ET
The Life Sciences Report Interviews DURECT Corp. President and CEO James Brown
DURECT Corp. (NASDAQ: DRRX) has a pipeline of drugs for a wide range of indications, from NASH to psoriasis to postoperative pain. In this interview with The Life Sciences Report, Dr. James Brown, DURECT's President and CEO, discusses the...
Mar 14, 2017 05:02 pm ET
DURECT Corporation Announces Fourth Quarter and Full Year 2016 Financial Results and Update of Programs
CUPERTINO, Calif., March 14, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2016 and provided a corporate update.  
Feb 24, 2017 04:30 pm ET
DURECT Corporation Invites You to Join its Fourth Quarter 2016 Earnings Conference Call
CUPERTINO, Calif., Feb. 24, 2017 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2016 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Tuesday, March 14, 2017 at 4:30 pm Eastern Time (1:30 pm Pacific Time).
Jan 30, 2017 08:00 am ET
DURECT Corporation Announces Update on DUR-928 Development Program
CUPERTINO, Calif., Jan. 30, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today provided an update on the DUR-928 development program.  DUR-928, our Epigenetic Regulator Program's lead product candidate, is an endogenous, small molecule, new chemical entity (NCE), which may have broad applicability in several metabolic diseases such as nonalcoholic steatohepatitis (NASH) and other liver conditions, and in acute organ injuries such as acute kidney injury (AKI).
Nov 03, 2016 09:00 am ET
The Life Sciences Report Examines Why the Election Is Not as Relevant to Drug Stocks as You Might Believe
Due to drug pricing controversies, there has been much concern about how the outcome of the upcoming election will affect pharmaceutical stocks. Dr. Len Yaffe of Stoc*Doc Partners sheds light on the issues in this analysis of drug price negotiation...
Oct 31, 2016 05:03 pm ET
DURECT Corporation Announces Third Quarter 2016 Financial Results and Update of Programs
CUPERTINO, Calif., Oct. 31, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the third quarter of 2016.  Total revenues were $3.7 million and net loss was $8.8 million for the three months ended September 30, 2016 as compared to total revenues of $4.7 million and net loss of $6.5 million for the three months ended September 30, 2015.    
Oct 31, 2016 05:02 pm ET
DURECT Corporation Announces Update on DUR-928 Development Program
CUPERTINO, Calif., Oct. 31, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today provided an update on the DUR-928 development program including a description of data from the first cohort of a Phase 1b study with DUR-928 in patients with nonalcoholic steatohepatitis (NASH).
Oct 21, 2016 05:30 pm ET
DURECT Corporation Invites You to Join its Third Quarter 2016 Earnings Conference Call
CUPERTINO, Calif., Oct. 21, 2016 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2016 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Monday, October 31, 2016 at 4:30 pm Eastern Time (1:30 pm Pacific Time).
Oct 07, 2016 09:00 am ET
The Life Sciences Report Examines How Analysts Keep Focus on DURECT's DUR-928
The FDA's recent Complete Response Letter for Remoxy, which is licensed by DURECT Corp. (NASDAQ: DRRX) to Pain Therapeutics, has not changed the view of several analysts who follow DURECT. They are focused on DUR-928 for NASH and impaired kidney...
Sep 26, 2016 08:05 am ET
DURECT's Licensee Pain Therapeutics Receives Complete Response Letter from FDA for REMOXY® ER (oxycodone) Extended-Release Capsules CII
CUPERTINO, Calif., Sept. 26, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for Pain Therapeutics' New Drug Application (NDA) for REMOXY® ER (oxycodone) extended-release capsules CII.  Based on its review, the FDA has determined that the NDA cannot be approved in its present form and specifies additional actions and data that are needed for drug approval.
Sep 09, 2016 09:00 am ET
The Life Sciences Report Examines Three Shots on Goal in Q4/16 for DURECT Corp.
With a trifecta of share-moving milestones anticipated in Q4/16, including possible FDA approval of abuse-resistant opioid Remoxy, Laidlaw & Co. Analyst Jim Molloy sees blue sky ahead for DURECT Corp. (NASDAQ: DRRX)Included in this article is:...
Sep 06, 2016 09:00 am ET
DURECT to Present at the Rodman & Renshaw Global Investment Conference
CUPERTINO, Calif., Sept. 6, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at the Rodman & Renshaw Global Investment Conference on Monday, September 12 at 9:35 a.m. Eastern Time.  The conference is being held at the Lotte New York Palace Hotel in New York City.  Institutional investors and analysts that are attending the conference may request a one-on-one meeting through the conference coordinators.
Aug 01, 2016 05:05 pm ET
DURECT Corporation Announces Second Quarter 2016 Financial Results and Update of Programs
CUPERTINO, Calif., Aug. 1, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the second quarter of 2016. Total revenues were $3.2 million and net loss was $9.0 million for the three months ended June 30, 2016 as compared to total revenues of $4.4 million and net loss of $5.5 million for the three months ended June 30, 2015.    
Jul 25, 2016 05:15 pm ET
DURECT Corporation Invites You to Join its Second Quarter 2016 Earnings Conference Call
CUPERTINO, Calif., July 25, 2016 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2016 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Monday, August 1, 2016 at 4:30 pm Eastern Time (1:30 pm Pacific Time).
Jul 14, 2016 02:37 pm ET
DURECT's Abuse-Deterrent Opioid Poised for FDA Approval
Oxycodone is a powerful and lucrative painkiller, but one with serious downsides. Dependency on the opioid has become a major issue medically, politically and, most profoundly­­, for the patients whose addictions have become debilitating or fatal....
Jul 01, 2016 10:05 am ET
DURECT Provides REMOXY® Update
CUPERTINO, Calif., July 1, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has announced that the U.S. Food and Drug Administration (FDA) has determined that an Advisory Committee meeting for REMOXY®, which had been tentatively scheduled for August 5, 2016, is unnecessary and will not be held. REMOXY was previously the subject of an Advisory Committee meeting in 2008. Pain Therapeutics also stated that the FDA advised them that the regulatory review of the REMOXY New Drug Application (NDA) remains active and on-going.
Jun 28, 2016 05:30 pm ET
DURECT to Present at the Cantor Fitzgerald Healthcare Conference
CUPERTINO, Calif., June 28, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Cantor Fitzgerald Healthcare Conference on Tuesday, July 12 at 8:00 a.m. Eastern Time.  The conference is being held at Le Parker Meridien Hotel in New York City.  Investors and analysts that are attending the conference may request a one-on-one meeting through the conference organizers at http://www.meetmax.com/sched/event_37633/investor_reg_new.html?attendee_role_id=INVESTOR.
May 31, 2016 09:30 am ET
DURECT to Present at the Jefferies Healthcare Conference
CUPERTINO, Calif., May 31, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Jim Brown, President and Chief Executive Officer, will be presenting at the Jefferies Healthcare Conference on Friday, June 10 at 1:30 pm Eastern Time. The conference is being held at the Grand Hyatt Hotel in New York.  Management will also be available for one-on-one meetings at this conference; interested institutional investors should request a one-on-one meeting through the conference coordinators.
May 19, 2016 10:05 am ET
DURECT Announces FDA Advisory Committee Meeting for REMOXY®
CUPERTINO, Calif., May 19, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has announced that an Advisory Committee of the U.S. Food and Drug Administration (FDA) will review the REMOXY® New Drug Application (NDA), in a joint meeting of the FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee tentatively scheduled for August 5, 2016.   Pain Therapeutics also stated that the FDA advised them that the Prescription Drug User Fee Act (PDUFA) date for the RE
May 11, 2016 10:05 am ET
DURECT Announces New REMOXY® Data being Presented at American Pain Society Meeting
CUPERTINO, Calif., May 11, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced researchers will present new data around REMOXY's abuse-deterrent properties at the 35th Annual Scientific Meeting of the American Pain Society (APS) meeting.  The scientific poster is titled "REMOXY: Human Abuse Potential Study of an Extended-Release Oxycodone Formulation."  Co-authors Lynn Webster and Nadav Friedmann are scheduled to present the data at APS on Thursday, May 12, 2016, from 3:45 to 5:15 pm Central Time.  This scientific poster will be available for review by the general public o
May 05, 2016 05:05 pm ET
DURECT Corporation Announces First Quarter 2016 Financial Results and Update of Programs
CUPERTINO, Calif., May 5, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the first quarter of 2016.  Total revenues were $3.6 million and net loss was $7.9 million for the three months ended March 31, 2016 as compared to total revenues of $4.8 million and net loss of $4.9 million for the three months ended March 31, 2015.    
Apr 29, 2016 01:15 pm ET
DURECT Announces Closing of Public Offering of Common Stock
CUPERTINO, Calif., April 29, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the closing of an underwritten public offering of 13,800,000 shares of its common stock, offered at a price of $1.25 per share to the public, including 1,800,000 shares purchased by the underwriters pursuant to their option.  All of the shares in the offering were sold by DURECT.  The gross proceeds to DURECT from this offering were approximately $17.3 million, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by DURECT.
Apr 28, 2016 05:30 pm ET
DURECT Corporation Invites You to Join its First Quarter 2016 Earnings Conference Call
CUPERTINO, Calif., April 28, 2016 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2016 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, May 5, 2016 at 4:30 pm Eastern Time (1:30 pm Pacific Time).
Apr 26, 2016 10:00 am ET
DURECT Announces Pricing of Public Offering of Common Stock
CUPERTINO, Calif., April 26, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock, offered at a price of $1.25 per share to the public.  The gross proceeds to DURECT from this offering are expected to be $15 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by DURECT.  All of the shares in the offering are to be sold by DURECT.  The offering is expected to close on or about April 29, 2016, subject to the satisfaction of customa
Apr 25, 2016 05:01 pm ET
DURECT Announces Proposed Public Offering of Common Stock
CUPERTINO, Calif., April 25, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it is offering, subject to market conditions, shares of its common stock in an underwritten public offering. DURECT anticipates using the net proceeds from this offering for general corporate purposes, which may include clinical trials, research and development activities, capital expenditures, selling, general and administrative costs and to meet working capital needs. All of the shares in the offering are to be sold by DURECT.
Apr 14, 2016 09:00 am ET
JonesTrading's George Zavoico Interviewed by The Life Sciences Report
While the vagaries of the 2016 political season create uncertainty in the biotech and pharmaceutical sectors, companies are moving ahead with innovative cell therapies, gene therapies and new, safer ways to deliver addictive drugs, and investors...
Apr 12, 2016 07:34 pm ET
DURECT Announces FDA Acceptance of REMOXY® NDA, PDUFA Date of September 25, 2016
CUPERTINO, Calif., April 12, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced its licensee, Pain Therapeutics (Nasdaq: PTIE), has been informed by the U.S. Food and Drug Administration (FDA) that the New Drug Application (NDA) for REMOXY®, an abuse-deterrent formulation of extended-release oxycodone (CII) capsules, is sufficiently complete to permit a substantive review, and that September 25, 2016 is the target action date under the Prescription Drug User Fee Act (PDUFA).   
Apr 07, 2016 06:00 pm ET
DURECT Announces POSIMIR® Program Update
CUPERTINO, Calif., April 7, 2016 /PRNewswire / -- DURECT Corporation (Nasdaq: DRRX) today announced that after the PERSIST Phase 3 trial for POSIMIR® was underway and enrolling patients at multiple sites, the Company received a letter from FDA advising the Company to make a number of amendments to the PERSIST trial.  One of the recommendations was to incorporate standard bupivacaine HCl as an active control. The Company had a follow-up call with the FDA this week to discuss the advice letter, as a result of which the Company has decided to implement the FDA's recommendations.  This change wi
Mar 29, 2016 12:15 pm ET
DURECT Announces Resubmission of REMOXY® New Drug Application to the U.S. Food and Drug Administration
CUPERTINO, Calif., March 29, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced its licensee, Pain Therapeutics (Nasdaq: PTIE), has resubmitted the New Drug Application (NDA) for REMOXY® (oxycodone capsules CII) to the U.S. Food and Drug Administration (FDA).   Pain Therapeutics has stated that they expect to be notified by the FDA of a Prescription Drug User Fee Act (PDUFA) action date within 30 days.  The original REMOXY NDA has a Priority Review Designation.  
Mar 17, 2016 09:00 am ET
Laidlaw & Co. Analyst Jim Molloy Interviewed by The Life Sciences Report
After a devastating start to 2016, biotech stocks have snapped back. Laidlaw & Co. analyst Jim Molloy likes the resurgence he's seeing in biotechnology share prices, but cautions that confirmation of a recovery will require cash-laden drug...
Feb 29, 2016 04:05 pm ET
DURECT Corporation Announces Fourth Quarter 2015 Financial Results and Update of Programs
CUPERTINO, Calif., Feb. 29, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended December 31, 2015. Total revenues were $5.2 million for the three months ended December 31, 2015 and $4.3 million for the three months ended December 31, 2014.  Net loss was $5.8 million for the three months ended December 31, 2015, compared to a net loss of $5.9 million for the same period in 2014.
Feb 18, 2016 04:30 pm ET
DURECT Corporation Invites You to Join its Fourth Quarter 2015 Earnings Conference Call
CUPERTINO, Calif., Feb. 18, 2016 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2015 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, February 29, 2016 at 4:30 pm Eastern Time (1:30 pm Pacific Time).
Feb 02, 2016 09:00 am ET
DURECT Corp.'s CEO James E. Brown Interviewed by The Life Sciences Report
Alza Corp. was a pioneer in the field of drug delivery, and that illustrious heritage continues in its spinout, DURECT Corp. (NASDAQ: DRRX), which has leveraged the technology to enable highly innovative, value-added products that may soon be on the...
Jan 28, 2016 05:00 pm ET
DURECT to Present at the BIO CEO & Investor Conference
CUPERTINO, Calif., Jan. 28, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan (Chief Financial Officer) will be presenting at the BIO CEO & Investor Conference on Monday, February 8 at 4:00 p.m. Eastern Time.  The conference is being held at the Waldorf-Astoria Hotel in New York City.  Investors and analysts that are attending the conference may request a one-on-one meeting through the conference organizers at https://www.bio.org/events/conferences/bio-ceo-partnering-resource-center.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.